Alpha Tau Medical Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the month of January 2026, with a specific reporting date of January 5, 2026. Alpha Tau Medical Ltd., a foreign private issuer based in Jerusalem, Israel, filed this report to disclose a material corporate development regarding its product pipeline.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The primary material change disclosed is a regulatory milestone. On January 5, 2026, the Company submitted its first Pre-Market Approval (PMA) Module to the U.S. Food and Drug Administration (FDA). This submission concerns the Alpha DaRT® device for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of specific risks and contingencies beyond the standard regulatory submission. The document explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the status of the FDA Pre-Market Approval (PMA) Module submission for Alpha DaRT®.
- Confirm the specific indications and scope of the cSCC treatment application.
- Review the attached press release (Exhibit 99.1) for detailed clinical data supporting the submission.
- Monitor future filings for FDA responses or requests for additional information regarding the PMA.